Home News

ROVI completes the manufacture of the first batches of Moderna vaccine

Laboratorios Farmacéuticos Rovi, S.A. (BME -Spanish Stock Exchanges and Markets: ROVI), a pan-European specialised company engaged in the research, development and marketing of biological specialties and a manufacturer with a high degree of technological

Wed, 13/01/2021 - 17:03 0 min
Download related document
No votes yet
 
Related
2025 Capital Markets Day presentation
ROVI forecasts that its 2024 operating revenue will be multiplied by between 1.5 and 1.8 in six years, driven primarily by an increase...
1 min
25/03/2025
2024 results press release
​​Operating revenue in 2024 was 763.7 million euros, a 7.9% decrease on 2023, mainly due to the performance of the contract...
3 min
25/02/2025
First nine months 2024 results press release
Operating revenue in the first nine months of 2024 was 564.6 million euros, a 5% decrease on the first nine months of 2023, mainly due...
4 min
07/11/2024